NCT03106155View on ClinicalTrials.gov

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

May 3, 2018

Study Completion Date

June 29, 2018

Conditions

Small Cell Lung Cancer

Interventions

DRUG

vistusertib (AZD2014)

vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.

Trial Locations (1)

06351

Samsung Medical center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Samsung Medical Center

OTHER